‘Poor Quality’ Submission: CellTrans’ Lantidra BLA Marked By Missing And Incongruent Data

 
• By Sue Sutter
  
Drug Review Profile: Lantidra
The FDA had to look beyond the missing and inconsistent data in the Lantidra BLA. • Source: Pink Sheet/Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews